Total Payments
$1,054
2024 Payments
$521.53
Companies
20
Transactions
49
Medicare Patients
1,880
Medicare Billing
$368,072
Payment Breakdown by Category
Food & Beverage$1,054 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,054 | 49 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $146.57 | 7 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $133.16 | 7 | $0 (2024) |
| Ardelyx, Inc. | $114.16 | 4 | $0 (2024) |
| Amgen Inc. | $96.02 | 4 | $0 (2024) |
| NxStage Medical, Inc. | $59.89 | 2 | $0 (2017) |
| Bayer Healthcare Pharmaceuticals Inc. | $59.05 | 3 | $0 (2024) |
| Fresenius USA Marketing, Inc. | $59.02 | 3 | $0 (2023) |
| Aurinia Pharma U.S., Inc. | $57.21 | 3 | $0 (2024) |
| GlaxoSmithKline, LLC. | $40.38 | 2 | $0 (2023) |
| Leadiant Biosciences, Inc. | $37.73 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $521.53 | 23 | Novartis Pharmaceuticals Corporation ($133.16) |
| 2023 | $172.29 | 8 | Leadiant Biosciences, Inc. ($37.73) |
| 2022 | $150.52 | 7 | AstraZeneca Pharmaceuticals LP ($69.01) |
| 2021 | $45.15 | 2 | AstraZeneca Pharmaceuticals LP ($45.15) |
| 2020 | $56.12 | 4 | Baxter Healthcare ($17.94) |
| 2019 | $37.77 | 2 | Relypsa, Inc. ($20.10) |
| 2018 | $11.13 | 1 | Amgen Inc. ($11.13) |
| 2017 | $59.89 | 2 | NxStage Medical, Inc. ($59.89) |
All Payment Transactions
49 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $25.73 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/06/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $27.15 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 09/17/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $18.77 | General |
| 08/27/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $20.54 | General |
| 08/13/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $16.71 | General |
| Category: DIABETES | ||||||
| 08/08/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $19.69 | General |
| Category: Cardio-renal | ||||||
| 08/06/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $19.96 | General |
| 08/01/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $30.03 | General |
| Category: Inflammation | ||||||
| 07/18/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $22.41 | General |
| 07/11/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $16.99 | General |
| Category: NEPHROLOGY | ||||||
| 07/09/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $21.92 | General |
| Category: Cardio-renal | ||||||
| 06/25/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $31.53 | General |
| Category: Inflammation | ||||||
| 06/18/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $30.65 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/13/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $21.69 | General |
| 06/04/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.05 | General |
| Category: DIABETES | ||||||
| 05/29/2024 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $13.53 | General |
| Category: Hyperkalemia | ||||||
| 05/23/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $21.69 | General |
| 05/15/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $30.28 | General |
| Category: GASTROENTEROLOGY | ||||||
| 04/23/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $36.69 | General |
| Category: IMMUNOLOGY | ||||||
| 04/04/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $23.26 | General |
| 03/08/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $27.50 | General |
| Category: GASTROENTEROLOGY | ||||||
| 01/23/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $4.80 | General |
| 01/11/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $19.96 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 12/13/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $17.44 | General |
| Category: Cardio-renal | ||||||
| 12/05/2023 | Vifor Pharma, Inc. | Veltassa (Drug), Korsuva | Food and Beverage | In-kind items and services | $19.80 | General |
| Category: Hyperkalemia | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 347 | 809 | $218,692 | $84,513 |
| 2022 | 8 | 424 | 779 | $208,276 | $78,478 |
| 2021 | 10 | 471 | 867 | $250,878 | $94,683 |
| 2020 | 12 | 638 | 1,221 | $311,456 | $110,398 |
Total Patients
1,880
Total Services
3,676
Medicare Billing
$368,072
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 90 | 259 | $49,500 | $24,477 | 49.4% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 16 | 77 | $60,289 | $21,872 | 36.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 86 | 252 | $34,663 | $15,743 | 45.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 67 | 84 | $24,950 | $8,122 | 32.6% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 12 | 26 | $17,028 | $6,210 | 36.5% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 24 | 50 | $15,870 | $2,902 | 18.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 35 | 36 | $10,541 | $2,616 | 24.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 17 | 25 | $5,851 | $2,572 | 44.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 93 | 223 | $42,816 | $19,047 | 44.5% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 11 | 62 | $51,522 | $17,727 | 34.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 114 | 235 | $33,135 | $13,914 | 42.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 78 | 87 | $27,840 | $9,636 | 34.6% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 12 | 31 | $21,762 | $7,620 | 35.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 47 | 55 | $12,981 | $4,455 | 34.3% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 36 | 46 | $10,534 | $2,815 | 26.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 20 | 27 | $5,697 | $2,549 | 44.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 13 | 13 | $1,989 | $714.37 | 35.9% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 25 | 97 | $80,607 | $28,825 | 35.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 124 | 283 | $40,175 | $17,081 | 42.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 85 | 167 | $32,528 | $14,567 | 44.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 83 | 89 | $28,480 | $9,951 | 34.9% |
| 90961 | Dialysis services (2-3 physician visits per month), patient 20 years of age and older | Office | 2021 | 17 | 34 | $23,868 | $8,399 | 35.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 44 | 53 | $12,491 | $4,489 | 35.9% |
| 90935 | Hemodialysis procedure with one physician evaluation | Facility | 2021 | 34 | 69 | $15,801 | $4,286 | 27.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 16 | 19 | $4,009 | $2,023 | 50.5% |
About Dr. Daranee Chewaproug, DO
Dr. Daranee Chewaproug, DO is a Nephrology healthcare provider based in Phila, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/19/2008. The National Provider Identifier (NPI) number assigned to this provider is 1285884825.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daranee Chewaproug, DO has received a total of $1,054 in payments from pharmaceutical and medical device companies, with $521.53 received in 2024. These payments were reported across 49 transactions from 20 companies. The most common payment nature is "Food and Beverage" ($1,054).
As a Medicare-enrolled provider, Chewaproug has provided services to 1,880 Medicare beneficiaries, totaling 3,676 services with total Medicare billing of $368,072. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Phila, PA
- Active Since 09/19/2008
- Last Updated 09/19/2008
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1285884825
Products in Payments
- LOKELMA (Drug) $127.72
- IBSRELA (Drug) $114.16
- Veltassa (Drug) $64.60
- TAVNEOS (Drug) $61.56
- System One (Device) $59.89
- Kerendia (Drug) $59.05
- Velphoro (Drug) $59.02
- LUPKYNIS (Drug) $57.21
- CARNITOR (Drug) $37.73
- JARDIANCE (Drug) $36.76
- ACTHAR (Biological) $36.69
- Crysvita (Drug) $27.15
- Parsabiv (Drug) $23.33
- BENLYSTA (Biological) $20.51
- JESDUVROQ (Drug) $19.87
- FARXIGA (Drug) $18.85
- Renal - PrisMax System (Device) $17.94
- AURYXIA (Drug) $17.67
- JYNARQUE (Drug) $16.99
- Vaprisol Dextrose in Plastic Container (Drug) $13.45
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Phila
Edward Filippone, Md, MD
Nephrology — Payments: $135,962
Nephrology $135,962
Dr. Imara Dissanayake, Md, MD
Nephrology — Payments: $15,290
Nephrology $15,290
Dr. Efua Asamoah-Odei, Md, MD
Nephrology — Payments: $3,001
Nephrology $3,001
Eric Newman, Do, DO
Nephrology — Payments: $1,028
Nephrology $1,028
Yoon Ahn, Md, MD
Nephrology
Nephrology